Skip to main content

Alector, Inc.

corporate_fare Company Profile

Alector, Inc.

ALEC·NASDAQ·Life Sciences·CIK 0001653087

Alector, Inc. is a clinical-stage biotechnology company that develops therapies for neurodegenerative diseases, focusing on areas with significant unmet medical needs. The company's work is based on advancements in disease biology, including the roles of misfolded or deficient proteins, lysosomal dysfunction, and disruptions in immune and neuronal pathways. Alector aims to develop product candidates that address diseases through targeted mechanisms, such as removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. The company is advancing a portfolio of programs focused on genetically validated targets, supported by its expertise in drug development, protein engineering, and antibody discovery. A key part of its strategy is the Alector Brain Carrier (ABC) platform, a proprietary blood-brain barrier (BBB) delivery technology designed to improve central nervous system exposure for various therapeutic types. This platform is being refined to enable effective brain delivery at clinically practical doses of antibodies, enzymes, and siRNA therapeutics. Alector also invests in biomarkers and biomarker assays to guide patient selection, demonstrate target and pathway engagement, and assess biological impact in clinical trials. Alector's portfolio includes nivisnebart (formerly AL101/GSK4527226), an investigational progranulin (PGRN)-elevating antibody. This candidate has completed enrollment in a placebo-controlled, double-blinded Phase 2 study for early Alzheimer's disease (AD) under a July 2021 Collaboration and License Agreement with Glaxo Wellcome UK Limited, a subsidiary of GlaxoSmithKline plc (GSK). The company's wholly owned programs include lead candidates in preclinical development for a brain-penetrant anti-amyloid beta antibody for Alzheimer's disease and a brain-penetrant GCase enzyme replacement therapy for Parkinson's disease (PD) and Lewy body dementia (LBD). Alector is also developing brain-penetrant siRNA programs targeting tau for Alzheimer's disease, α-synuclein for Parkinson's disease, and NLRP3, which has potential applications across multiple neurodegenerative conditions. Nivisnebart is an investigational human recombinant monoclonal antibody designed to elevate PGRN levels in the brain, with pharmacokinetic and pharmacodynamic properties potentially suitable for treating prevalent neurodegenerative diseases.

Alector, Inc. (NASDAQ:ALEC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for ALEC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for ALEC spans 8-K, 424B5, 10-Q, S-3.

Recent high-impact activity:

  • Alector Posts $124.6M Q3 Net Income on GSK Deferred Revenue; Cash Runway to 2H 2029
  • Alector Swings to $124.6M Q3 Profit on GSK Deferred Revenue, Cash Runway to 2H 2029
  • Alector Prices $75M Offering at 7.3% Premium to Raise Cash Into 2027
  • Alector Licenses AL050 to Genentech for $100M Upfront, Extends Cash Runway into 2029
  • Alector Lands $100M Upfront, Up to $1.17B in Milestones from Genentech for Brain-Penetrant GCase Therapy

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$21.05M
Net Income
-$142.93M
Diluted EPS
-$1.39
Op. Cash Flow
-$184.03M
Free Cash Flow
-$184.07M
Operating Income
-$156.01M
Cash & Equivalents
$65.8M
Total Debt
$9.69M
Debt / Equity
0.32×
Net Margin
-6.79×
Shares Outstanding
110.36M sh
Source: 10-K · filed 2026-02-25 · accession 0001193125-26-071593

Short Interest & Short Volume

3.62 days to cover

FINRA reported short interest of 8,393,562 shares in ALEC as of the October 30, 2026 settlement, a 18.1% decrease from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 54.4% of ALEC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,393,562 shares as of October 30, 2026
Change vs prior period▼ 18.1%
Days to cover3.62 at avg daily volume of 2,317,570
Daily short volume (FINRA facilities)54.4% of 632,267 shares on November 20, 2026
5-day average short volume51.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for ALEC, detected from its recent SEC filings · based on capital-structure filings through 2026-10-16.

1 recent capital raise

36.6M Shares Priced at $2.05 · Net Proceeds About $70.2M

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$2.26 -1.74% today
52-week range · as of 2026-11-05 $1.09 – $2.76
Market cap
$347.63M
Volume
2M (0.9× avg)
3-mo avg 2.1M
Live data · 2026-11-21 10:53 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALEC - Latest Insights

ALEC
Nov 05, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $2.26 info
Change: +$0.080 (+4%) info
Market Cap: $347.628M info
ALEC
Nov 05, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $2.26 info
Change: +$0.0992 (+5%) info
Market Cap: $347.628M info
ALEC
Oct 16, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.02
Real-time Price: $2.26 info
Change: +$0.240 (+12%) info
Market Cap: $347.628M info
ALEC
Oct 05, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.82
Real-time Price: $2.26 info
Change: +$0.4399 (+24%) info
Market Cap: $347.628M info
ALEC
Oct 05, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $2.37
Real-time Price: $2.26 info
Change: -$0.110 (-5%) info
Market Cap: $347.628M info
ALEC
Sep 16, 2026, 12:51 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $2.26 info
Change: +$0.260 (+13%) info
Market Cap: $347.628M info
ALEC
Aug 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.78
Real-time Price: $2.26 info
Change: +$0.4798 (+27%) info
Market Cap: $347.628M info
ALEC
Jul 08, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $1.83
Real-time Price: $2.26 info
Change: +$0.430 (+23%) info
Market Cap: $347.628M info
ALEC
Jul 08, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.83
Real-time Price: $2.26 info
Change: +$0.430 (+23%) info
Market Cap: $347.628M info
ALEC
May 07, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.41
Real-time Price: $2.26 info
Change: -$0.150 (-6%) info
Market Cap: $347.628M info
ALEC
May 07, 2026, 5:13 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $2.41
Real-time Price: $2.26 info
Change: -$0.150 (-6%) info
Market Cap: $347.628M info
ALEC
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $2.44
Real-time Price: $2.26 info
Change: -$0.180 (-7%) info
Market Cap: $347.628M info
ALEC
May 07, 2026, 4:17 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.44
Real-time Price: $2.26 info
Change: -$0.180 (-7%) info
Market Cap: $347.628M info
ALEC
Mar 12, 2026, 4:08 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $2.21
Real-time Price: $2.26 info
Change: +$0.050 (+2%) info
Market Cap: $347.628M info
ALEC
Feb 25, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.39
Real-time Price: $2.26 info
Change: -$0.130 (-5%) info
Market Cap: $347.628M info
ALEC
Feb 25, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.39
Real-time Price: $2.26 info
Change: -$0.130 (-5%) info
Market Cap: $347.628M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets